Healthy Clinical Trial
Official title:
The Influence of Cortical Lateralization on Selective Motor Control of the Arm Swing During Independent Walking After Stroke.
The upper limbs play an essential role for safe and efficient walking in healthy persons and persons post-stroke. Nevertheless, in current post-stroke gait rehabilitation (research) the upper limbs are barely targeted. To address this gap, my project aims to investigate the selective motor control of the upper limbs during walking and the contribution of the cortical activity to the arm swing in independent walkers after stroke. To gain insight in the direct effects of stroke on the arm swing, the primary motor control of the arm swing will be evaluated by determining muscle synergies (i.e group of muscles working together as a task-specific functional unit). Additionally, the cortical activity (EEG-analysis) during walking of persons post-stroke will be compared to healthy controls and the relationship between stroke-induced changes in cortical activity and arm swing deviations will be assessed. Furthermore, I will evaluate whether improvements in cortical activity relate to improvements in primary motor control of the arm swing. This innovative project will be the first to investigate the direct coupling between the cortex and the muscle synergies in persons post-stroke during independent walking to investigate the arm swing. These fundamental insights in the primary motor control of the arm swing and the contribution of the cortical activity will allow to develop targeted interventions aiming to improve arm swing and as such optimize post-stroke gait rehabilitation. Research questions: 1. How can muscle synergies explain arm swing alterations in independent walkers after stroke? 2. How do stroke-induced changes in cortical activity relate to arm swing deviations in persons after stroke? 3. Are changes in primary motor control of the upper limb during walking related to normalization of brain activity in independent walkers after stroke?
Status | Recruiting |
Enrollment | 84 |
Est. completion date | September 30, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Stroke Inclusion Criteria: - First-ever, ischemic and cerebral stroke - Maximum one-year post-stroke - Able to walk at least 10 minutes (FAC = 3) - Presence of upper limb paresis (NIHSS item 5a/b > 0) Exclusion Criteria: - Other neurological disorders Healthy controls Inclusion criteria: - Older than 18 years - Able to walk at least 10 minutes Exlusion criteria: - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Belgium | Ghent University Hospital | Ghent | Oost-Vlaanderen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent | University Ghent, Vrije Universiteit Brussel, VU University of Amsterdam |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | National Institutes of Health Stroke Scale (NIHSS) | Quantifies the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. | Single point of assessment at inclusion (only for stroke survivors) | |
Other | National Institutes of Health Stroke Scale (NIHSS) | Quantifies the general impairment caused by a stroke after a follow-up period of three months. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Other | Fugl-Meyer assesment - Upper limbs | Assesses specifc motor impairments of the upper limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. | Single point of assessment at inclusion (only for stroke survivors) | |
Other | Fugl-Meyer assesment - Upper limbs | Assesses specifc motor impairments of the upper limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Other | Tardieu scale | Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). | Single point of assessment at inclusion (only for stroke survivors) | |
Other | Tardieu scale | Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Other | 10 Meter Walking Test | Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). | Single point of assessment at inclusion (only for stroke survivors) | |
Other | 10 Meter Walking Test | Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Other | Fugl-Meyer assesment - Lower limbs | Assesses specifc motor impairments of the lower limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. | Single point of assessment at inclusion (only for stroke survivors) | |
Other | Fugl-Meyer assesment - Lower limbs | Assesses specifc motor impairments of the lower limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Primary | Number of muscle synergies | The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined:
tibialis anterior, gastrocnemius lateralis soleus vastus medialis vastus lateralis rectus femoris biceps femoris gluteus medius erector spinae latissimus dorsi anterior deltoid posterior deltoid biceps brachii triceps brachii |
Single point of assessment at inclusion | |
Primary | Number of muscle synergies | The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors after a follow-up period of three months. Following muscles will be examined:
tibialis anterior, gastrocnemius lateralis soleus vastus medialis vastus lateralis rectus femoris biceps femoris gluteus medius erector spinae latissimus dorsi anterior deltoid posterior deltoid biceps brachii triceps brachii |
Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Primary | Weight of muscle synergies | The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls.
The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles: tibialis anterior, gastrocnemius lateralis soleus vastus medialis vastus lateralis rectus femoris biceps femoris gluteus medius erector spinae latissimus dorsi anterior deltoid posterior deltoid biceps brachii triceps brachii |
Single point of assessment at inclusion | |
Primary | Weight of muscle synergies | The number or distribution of muscle weightings within a synergy during walking in stroke survivors after a follow-up period of three months.
The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles: tibialis anterior, gastrocnemius lateralis soleus vastus medialis vastus lateralis rectus femoris biceps femoris gluteus medius erector spinae latissimus dorsi anterior deltoid posterior deltoid biceps brachii triceps brachii |
Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Primary | Brain symmetry index (BSI) | The amount of cortical lateralization during walking in stroke survivors compared to healthy controls. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. | Single point of assessment at inclusion | |
Primary | Brain symmetry index (BSI) | The amount of cortical lateralization during walking in stroke survivors after a follow-up period of three months. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Secondary | Upper limb kinematics | Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) | Single point of assessment at inclusion | |
Secondary | Upper limb kinematics | Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) | Single point of assessment 3 months after inclusion (only for stroke survivors) | |
Secondary | Cortico-synergy coherence | The amount of coherence (i.e. phase locking) between the muscle synergies and cortical activity during walking in stroke survivors compared to healthy controls. Higher values (0-1) indicate a better linear association. | Single point of assessment at inclusion | |
Secondary | Cortico-synergy coherence | The amount of coherence (i.e phase locking) between the muscle synergies and cortical activity during walking in stroke survivors after a follow-up period of three months. Higher values (0-1) indicate a better linear association. | Single point of assessment 3 months after inclusion (only for stroke survivors) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |